#Blood Cancer Diagnostics Market Share

[industryforecastnews]

Blood Cancer Diagnostics Market To Reach USD 16.04 Billion By 2030

Blood Cancer Diagnostics Market Growth & Trends

The global blood cancer diagnostics market size is expected to reach USD 16.04 billion by 2030, registering a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing incidence of blood malignancies, such as leukemia, lymphoma, and myeloma. The market is further expected to grow significantly due to the increasing elderly population, which is more susceptible to chronic diseases, including blood cancer. In addition, technological advancements, including NGS and other molecular diagnostic techniques, are improving the accuracy & efficiency of diagnosis, which is likely to drive the market over the forecast period.

Over the past decade, significant advancements have been made in approaches to blood cancer diagnostics, all aimed at reducing the growing incidence of diseases and their mortality. While these advancements have been well-documented to increase early cancer detection, there have been considerable advancements. For instance, NGS has enabled the analysis of the entire genome of cancer cells, providing insights into genetic mutations that guide precise diagnosis and tailored treatments. In October 2022, OGT, a Sysmex group, introduced a range of new offerings to augment its expanding NGS product suite. Notably, the SureSeq Myeloid Plus panel was designed to identify genetic mutations associated with various Myeloid disorders, enhancing the company’s capabilities in this critical area of research.

Molecular imaging techniques, such as SPECT/CT, PET, and flow cytometry, utilize molecular imaging agents to detect indicative molecular markers at different disease stages, aiding detection & monitoring. Such advancements in imaging technologies offer improved accuracy and early detection capabilities, driving the market. The global players are introducing automatic imaging tests and systems to boost their market share. For instance, in May 2023, Sysmex Corporation announced the launch of the Clinical Flow Cytometry System in Japan. The system includes Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products. This system enables laboratories to automate the entire process of flow cytometry testing, from sample preparation to the reporting of measurement results, contributing to higher efficiency & testing standardization.

Governments across the world have recognized the immense healthcare burden posed by rising incidences, including hematological malignancies such as leukemia & lymphoma. In response, many countries have launched comprehensive national cancer control programs that prioritize early detection and screening efforts. For instance, the American Association of Cancer Research recently launched the Beau Biden Cancer Moonshot initiative to accelerate cancer research and make preventive screening more accessible & affordable for U.S. citizens.

Some of the key players in the market are Illumina, InVivoScribe, Ipsogen (Qiagen), Asuragen(Bio-Techne), Danaher Corporation, Abbott, SkylineDx, Adaptive Technologies, Bio-Rad Laboratories and others. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in September 2023, Adaptive Technologies launched Epic integration for clonoSEQ, a molecular diagnostic test for MRD monitoring in blood cancers. This integration allows healthcare providers to order and review clonoSEQ test results directly within Epic's EHR system, streamlining clinical decision-making and improving patient care.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/blood-cancer-diagnostics-market-report

Blood Cancer Diagnostics Market Report Highlights

Based on product, the assay kits and reagents accounted for the largest revenue share of the blood cancer diagnostics market in 2023. This high share is attributable to assay kits & reagents being designed to detect specific biomarkers, genetic mutations, and other indicators, enabling healthcare professionals to diagnose & treat the disease more effectively

Based on tests, blood tests segment dominated the market and accounted for the largest share in 2023. This can be attributed to increasing innovation and availability of blood test kits for blood cancer detection

Based on end use, hospitals and clinics dominated the market with the largest share of blood cancer diagnostics market in 2023. This is attributable to growing demand in forensic labs and hospital medical labs for disease diagnosis, blood cell counts, blood typing. Furthermore, Developments in hospital laboratories are crucial to address the evolving needs of patients, and more hospitals aim to provide a wide range of services in their settings

North America dominated the market due to the presence of a large number of major market players, North America has a high prevalence of chronic diseases like leukemia These diseases require regular monitoring and diagnostic testing, fueling the demand for advanced diagnostic tools and technologies

Asia Pacific is expected to witness the fastest growth over the forecast period from 2024 to 2030, due to the presence of manufacturers with innovative devices manufacturing capabilities coupled with accelerated diagnostic research capabilities

Blood Cancer Diagnostics Market Segmentation 

Grand View Research has segmented the global blood cancer diagnostics market based on product, test, end use, and region:

Blood Cancer Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)

Instruments

Assay Kits and Reagents

Blood Cancer Diagnostics Test Outlook (Revenue, USD Million, 2018 - 2030)

Blood Tests

Imaging Tests

Biopsy

Molecular Test

Blood Cancer Diagnostics End Use Outlook (Revenue, USD Million, 2018 - 2030)

Hospitals and Clinics

Diagnostic Labs

Research Institutes

Blood Cancer Diagnostics Regional Outlook (Revenue in USD Million, 2018 - 2030)

North America

U.S.

Canada

Mexico

Europe

UK

Germany

France

Italy

Spain

Sweden

Denmark

Norway

Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

Latin America

Brazil

Argentina

Middle East and Africa

Saudi Arabia

South Africa

UAE

Kuwait

List Of Key Players in The Blood Cancer Diagnostics Market

Abbott

Illumina

InVivoScribe

Ipsogen (Qiagen)

Asuragen(Bio-Techne)

Danaher Corporation

Sequenta (Adaptive biotechnologies)

SkylineDx

Bio-Rad Laboratories

Alercell

Sophia Genetics

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/blood-cancer-diagnostics-market-report

[marketresearchintent]

Blood Group Typing Market Analysis: New Opportunities in the Healthcare Sector

The Blood Group Typing Market is expected to grow at a rapid pace over the coming years. In 2023, the market was valued at USD 1.9 billion, and by 2030, it's projected to surpass USD 3.3 billion, growing at a compound annual growth rate (CAGR) of 8.2%. This surge in market value highlights the increasing demand for blood typing in various healthcare sectors.

What is Blood Group Typing?

Blood group typing is the process of determining an individual's blood group, typically classified into A, B, AB, or O types. This crucial medical procedure ensures compatibility for blood transfusions, organ transplants, and managing pregnancies where blood group incompatibility may lead to complications. It also plays an important role in research, diagnostics, and therapeutics.

Why is the Blood Group Typing Market Growing?

Several factors contribute to the rapid growth of the blood group typing market:

Rising Demand for Blood Transfusions: The growing number of surgeries and trauma cases has driven the need for safe and compatible blood transfusions.

Advancements in Technology: With the advent of advanced testing technologies, blood typing has become quicker and more accurate.

Increasing Prevalence of Chronic Diseases: As chronic diseases like cancer and cardiovascular conditions become more common, the need for blood transfusions, organ transplants, and diagnostic tests rises.

Government Initiatives: Government health agencies across the globe are launching campaigns to improve healthcare infrastructure, which includes better access to blood banks and safe transfusion practices.

Access Full Report @ https://intentmarketresearch.com/latest-reports/blood-group-typing-market-3123.html  

Key Segments of the Blood Group Typing Market

1. Based on Products

Consumables: Reagents, anti-sera, and red blood cells that are essential for blood typing procedures.

Instruments: Machines used in hospitals and laboratories for blood typing tests.

Services: Outsourcing services for hospitals and laboratories to perform blood group testing.

2. Based on Test Type

Antibody Screening: Detects antibodies in the blood that may cause immune reactions.

HLA Typing: Human leukocyte antigen typing is often used in organ transplantation to ensure compatibility.

ABO Blood Group Typing: The most common test, determining whether a person has blood type A, B, AB, or O.

Crossmatching: Ensures compatibility between donor and recipient blood before a transfusion.

3. Based on Technique

PCR-Based Testing: Polymerase chain reaction (PCR) testing is becoming popular due to its accuracy in detecting rare blood types.

Microarray Testing: A cutting-edge technique that offers detailed insights into blood group antigens.

Gel Agglutination: A traditional method where blood cells clump together to reveal their type.

4. Based on End-User

Hospitals and Clinics: The largest users of blood typing services, especially in emergency care, surgeries, and transfusions.

Blood Banks: Critical for maintaining safe blood supplies for hospitals and clinics.

Diagnostic Laboratories: Play a key role in providing accurate blood typing for various medical needs.

Research Institutes: Blood typing is essential in biomedical research and the development of new medical treatments.

Geographical Insights into the Blood Group Typing Market

North America

North America dominates the global blood group typing market, thanks to its advanced healthcare infrastructure and high demand for blood transfusions. The U.S. leads the region with significant investments in healthcare research and technological advancements.

Europe

Europe holds the second-largest market share, driven by increased demand for organ transplants and blood donations. Countries like Germany, the UK, and France are key players in the region.

Asia-Pacific

Asia-Pacific is the fastest-growing market, with a rapidly improving healthcare infrastructure, especially in countries like China, India, and Japan. Increased government initiatives and rising awareness of safe blood transfusion practices are fueling growth in this region.

Latin America and the Middle East

These regions are experiencing moderate growth, with improving healthcare systems and increased focus on safe transfusion practices. Brazil, Saudi Arabia, and the UAE are emerging as key markets.

Download Sample Report @ https://intentmarketresearch.com/request-sample/blood-group-typing-market-3123.html 

Technological Advancements in Blood Group Typing

Technological innovations have dramatically improved the accuracy and speed of blood group typing. Some of the most noteworthy advancements include:

Automation: Automated blood typing machines reduce human error and streamline the testing process.

DNA-Based Testing: Genetic testing methods like PCR and next-generation sequencing (NGS) have made it easier to identify rare blood types.

Artificial Intelligence: AI-driven platforms can now analyze blood typing data more efficiently, predicting rare blood types and crossmatching results with greater precision.

Challenges in the Blood Group Typing Market

Despite its rapid growth, the blood group typing market faces several challenges:

High Cost of Advanced Technologies: While innovative testing methods improve accuracy, they also raise costs, limiting access in some regions.

Limited Awareness in Low-Income Countries: In developing countries, there is still a lack of awareness regarding the importance of safe blood transfusions.

Regulatory Hurdles: Compliance with government regulations varies by region, sometimes slowing the approval process for new technologies.

Key Players in the Blood Group Typing Market

Several companies are leading the charge in the global blood group typing market:

Bio-Rad Laboratories: Specializing in diagnostics and testing solutions.

Grifols: A global leader in plasma-derived medicines and transfusion diagnostics.

Ortho Clinical Diagnostics: A top player in immunohematology and blood typing products.

Immucor: Focuses on improving transfusion and transplantation diagnostics.

Future Outlook of the Blood Group Typing Market

The future of the blood group typing market looks promising, with continued growth expected through 2030. Some key trends include:

Increased Investment in R&D: Research into advanced blood typing methods will likely continue, focusing on automation, accuracy, and cost reduction.

Emerging Markets: Countries with developing healthcare systems are investing in better blood typing technologies, creating new growth opportunities.

Personalized Medicine: The rise of personalized treatments will likely drive demand for more precise blood typing methods to ensure compatibility in therapies like immunotherapy and gene editing.

Conclusion

The global blood group typing market is on a path of exponential growth, driven by technological advancements, rising demand for blood transfusions, and government initiatives. With the market projected to surpass USD 3.3 billion by 2030, the future looks bright for companies and healthcare providers in this field. As the industry continues to innovate, the accuracy and accessibility of blood group typing will only improve, saving more lives and ensuring safer medical procedures.

FAQs

What is the CAGR of the blood group typing market from 2024 to 2030? The market is expected to grow at a CAGR of 8.2% during this period.

What is the importance of blood group typing? Blood group typing ensures compatibility for blood transfusions, organ transplants, and other medical procedures, reducing the risk of complications.

Which regions are leading the blood group typing market? North America holds the largest market share, followed by Europe and the rapidly growing Asia-Pacific region.

What are the major technologies used in blood group typing? Key technologies include PCR-based testing, microarray testing, and gel agglutination methods.

What are the major challenges facing the blood group typing market? Challenges include the high cost of advanced technologies, limited awareness in developing regions, and regulatory hurdles.

About Us

Intent Market Research (IMR) is dedicated to delivering distinctive market insights, focusing on the sustainable and inclusive growth of our clients. We provide in-depth market research reports and consulting services, empowering businesses to make informed, data-driven decisions.

Our market intelligence reports are grounded in factual and relevant insights across various industries, including chemicals & materials, healthcare, food & beverage, automotive & transportation, energy & power, packaging, industrial equipment, building & construction, aerospace & defense, and semiconductor & electronics, among others.

We adopt a highly collaborative approach, partnering closely with clients to drive transformative changes that benefit all stakeholders. With a strong commitment to innovation, we aim to help businesses expand, build sustainable advantages, and create meaningful, positive impacts.

Contact Us

sales@intentmarketresearch.com

US: +1 463-583-2713

[tamanna31]

Blood Screening Market 2023- Business Planning Research and Resources, Revenue, and Forecasts 2030

Blood Screening Market Size & Trends

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly. 

Blood Screening Market Segmentation

Grand View Research has segmented the global blood screening market based on technology, product, and region:

Technology Outlook (Revenue, USD Million, 2018 - 2030)

Nucleic Acid Amplification Test (NAT)

ELISA

Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

Next Generation Sequencing

Western Blotting

Product Outlook (Revenue, USD Million, 2018 - 2030)

Reagent

Instrument

Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Europe

UK

Germany

France

Italy

Spain

Sweden

Norway

Denmark

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Latin America

Brazil

Mexico

Argentina

Middle East and Africa

Saudi Arabia

South Africa

UAE

Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports.

The global embolic protection devices market size was valued at USD 612.9 million in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030. 

The global covered stent market size was estimated at USD 1.13 billion in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030. 

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.

For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.

Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.

Key Blood Screening Companies:

Abbott

Danaher Corporation (Beckman Coulter)

Becton Dickinson and Company

Bio-Rad Laboratories, Inc.

Hoffman-La Roche Ltd.

Grifols, S.A.

Ortho-Clinical Diagnostics, Inc.

Siemens Healthcare GmbH

Thermo Fisher Scientific, Inc.

SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research. 

[communicationblogs]

Biomarkers Market — Forecast(2024–2030)

The market for Biomarkers is classified into five categories based on types, application areas, therapeutic segments, products and by end users, each of these segments are further broken down into sub-segments to give a comprehensive analysis of global biomarkers market.

Download Sample 

The overall market has also been presented from the perspective of different geographic locations and key economies in this market. Competitors are highlighted and market players are profiled with attributes covering company overview, financial overview, business strategies, product portfolio and recent developments. Market shares of each of the prominent players for 2024 are detailed.

The market is largely dominated by North America which accounted for about half of the global share. APAC is a promising market and is opening gateways for new manufacturers.

Enquiry Before Buying 

The report also provides a detailed qualitative analysis of the factors responsible for driving and hindering the growth of the Biomarkers market and future opportunities that can propel the market.

The report contains the most detailed and in-depth segmentation and analysis of the Global Biomarkers Market during the forecast period 2024 –2030.

Schedule a call 

Types of biomarkers include:

Genetic: Variations in DNA associated with diseases or conditions.

Proteomic: Specific proteins or peptides that indicate the presence or progression of a disease.

Metabolic: Changes in metabolites that reflect altered metabolic pathways.

Imaging: Visual indicators of disease states obtained through imaging techniques like MRI or PET scans.

Buy Now

Applications:

Diagnosis: Identifying diseases (e.g., elevated PSA levels for prostate cancer).

Prognosis: Predicting disease outcomes (e.g., genetic mutations indicating cancer recurrence).

Treatment Monitoring: Evaluating treatment effectiveness and adjusting therapies (e.g., monitoring blood glucose in diabetes).

Drug Development: Guiding the development and efficacy of new therapies.

Challenges include variability across individuals, standardization of testing methods, and ethical issues related to privacy. Future advancements aim to enhance personalized medicine, integrate multi-omics approaches, and improve early disease detection.

Sample Companies Profiled in this Report are:

EKF Diagnostics Holdings plc

Meso Scale Diagnostics, LLC

Singulex, Inc.

BioSims Technologies

Cisbio Bioassays etc…

To get more information Click Here.

[creativeera]

DNA and RNA Sample Preparation Market is Estimated to Witness High Growth Owing to Increasing Adoption

The DNA and RNA sample preparation market involves processes associated with isolation, extraction, purification and quantification of nucleic acids DNA and RNA from various sources like tissues, blood, sperm, cells etc. for downstream applications in genomics, molecular diagnostics, personalized medicine and others. The sample preparation is a critical and initial step before conducting various genomic tests including Next Generation Sequencing, polymerase chain reaction and other assays. Growing awareness and adoption of precision medicine and genetic/molecular testing is driving demand for efficient nucleic acid isolation and downstream analysis.

The Global DNA and RNA Sample Preparation Market is estimated to be valued at US$ 2262.46 Mn in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast period 2024 To 2031. Key Takeaways Key players operating in the DNA and RNA sample preparation are Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., DiaSorin S.p.A, F. Hoffmann-La Roche, Miroculus, Inc., Illumina, Inc., PerkinElmer, Inc., QIAGEN, Sigma Aldrich Corp., Tecan Group AG, and Thermo Fisher Scientific, Inc. Growing prominence of personalized medicine is creating opportunities for development of new sample preparation methods and kits which can extract nucleic acids from various types of samples. Rising incidence of chronic and infectious diseases worldwide is increasing diagnostic testing which will propel sample preparation market growth. Global expansion of key market players through acquisitions and partnerships with regional diagnostic labs and research institutes will further augment market revenues. Market Drivers Increasing funding for Genomic and genetic research from government bodies as well as private sector is one of the key factors driving the DNA and RNA Sample Preparation Market Size. Government initiatives aimed at large scale population screening and clinical testing for various genetic disorders, infectious diseases and cancers are also creating demand for high throughput nucleic acid preparation. Growing geriatric population and rising healthcare spending in developing nations also provides growth opportunities for market players in the forecast period.

PEST Analysis Political: Laws and regulations imposed by governments for research using DNA and RNA samples could impact the market. Changes in healthcare policies will also have effects. Economic: Factors like GDP growth, income levels, healthcare spending will drive demand. Rise in research activities and focus on precision medicine boost the market. Social: Growing awareness about personalized medicine and importance of genetic testing are important. Social trends also promote preventive healthcare and wellness. Technological: Advancements in fields like next generation sequencing, lab automation, bioinformatics are key for market growth. Miniaturization and portability of equipment expand applications. Developments in sample collection and storage methods improve efficiency. Geographical regions where the market in terms of value is concentrated include North America and Europe. North America accounts for the largest share in the global market due to presence of well-established healthcare industry and research institutes. Europe also captures notable share due to growing biotech sector and research funding. The Asia Pacific region is projected to be the fastest growing market during the forecast period. This is attributed to factors such as increasing healthcare expenditure, growing awareness, expanding biotech industry and rising government investments in research. Countries like China, India offer growth opportunities as they focus on healthcare infrastructure development.

Get more insights on DNA And RNA Sample Preparation Market

Also read related article on Surgical Robots Market

Discover the Report for More Insights, Tailored to Your Language

French

German

Italian

Russian

Japanese

Chinese

Korean

Portuguese

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.

(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

[colinwilson11]

Soft Tissue Sarcoma Market To Grow Significantly Due To Increasing R&D Investment By Key Players

The soft tissue sarcoma market is a rapidly emerging field owing to increasing R&D investment by key players. Soft tissue sarcomas are rare cancers that develop in supporting or connective tissues like fat, muscle, blood vessels, deep skin tissues, and nerves. Some of the common types include gastrointestinal stromal tumors, uterine sarcomas, and rhabdomyosarcoma.

Soft tissue sarcomas account for about 1% of all adult cancers. While surgery is the mainstay for treatment of localized disease, advanced cases often require chemotherapy and targeted drug therapy.

The Soft Tissue Sarcoma Market is estimated to be valued at US$ 315 Mn in 2024 and is expected to exhibit a CAGR of 4.2% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the soft tissue sarcoma market are Pfizer, Eli Lilly, Johnson & Johnson, GSK (GlaxoSmithKline), and Roche.

The growing incidence of soft tissue sarcoma cases globally is a major factor driving market growth. Soft tissue sarcomas affected over 13,000 individuals in the United States in 2020 according to statistics.

Technological advancements like targeted drug therapy and development of biomarker assays are expanding treatment options and improving clinical outcomes for soft tissue sarcoma patients.

Market Trends

Increased focus on personalized medicine - Researchers are investigating molecular diagnostic tests and targeted therapies customized to a patient's tumor genetics which may improve response rates.

Combination therapy gaining traction - Combining drugs that work through different mechanisms is a promising approach and ongoing studies are evaluating combinations of chemotherapy with immunotherapies.

Market Opportunities

Immunotherapy emerging as a viable treatment option - Drugs that activate the immune system like checkpoint inhibitors have shown survival benefits in certain sarcoma subtypes creating new opportunities.

Companion diagnostics can guide therapy selection - Development of reliable biomarkers can help identify patients likely to respond to specific therapies and avoid treatment toxicity.

Impact Of COVID-19 On Soft Tissue Sarcoma Market Growth

The COVID-19 pandemic has significantly impacted the soft tissue sarcoma market. During the initial phases of the pandemic in 2020, most hospitals and clinics shifted their focus towards COVID care, which led to postponement of non-emergency surgeries and treatments. This impacted the diagnosis and treatment rates of soft tissue sarcomas. Patients also delayed their appointments and screenings fearing exposure to the virus in healthcare settings. This interrupted the continuity of care and follow-ups, posing challenges to sarcoma management. However, with increased availability of COVID vaccines and resumption of healthcare services from 2021, the market is slowly recovering. There is pent-up demand for diagnostic tests and treatments that were delayed during the peak pandemic phases. Hospitals have implemented strict safety protocols to reassure patients and ensure continuity of sarcoma management. Telehealth and home care services also aided in reducing disruption during lockdowns. Still, workforce shortages in the healthcare sector continue to pose operational difficulties. The long-term impact of delayed diagnoses and treatments remains to be seen. Market players are focusing on improving access to therapies through innovative drug delivery mechanisms and digital solutions.

Geographical Regions With Highest Soft Tissue Sarcoma Market Value

In terms of value, North America dominated the soft tissue sarcoma market as of 2021, owing to established healthcare infrastructure, high adoption of advanced diagnostic tools and therapies, and presence of key market players in the US and Canada. Within the region, the United States accounted for the major share. Europe is another prominent regional market, led by countries like Germany, United Kingdom, France, and others. Growing research on targeted therapies and partnerships between drug makers and cancer institutes are driving market growth across Europe. The Asia Pacific region is poised to be the fastest growing soft tissue sarcoma market over the forecast period due to rising healthcare expenditure, large patient population, and increasing awareness.

Fastest Growing Region For The Soft Tissue Sarcoma Market

The Asia Pacific region holds immense growth potential for the soft tissue sarcoma market and is expected to be the fastest growing region between 2024- 2031. This is attributed to factors like increasing healthcare access and spending in populous countries like China and India, rising incidence of sarcomas accompanying aging demographics, and improving diagnostic infrastructure. Furthermore, growing collaborations between global pharmaceutical companies and regional market players are boosting availability of advanced treatment options. Initiatives to spread awareness about rare cancers are also propelling regional growth. With economic expansion and growing focus on non-communicable diseases, the soft tissue sarcoma market is poised for strong growth across Asia Pacific.

Get more insights on this topic:  https://www.trendingwebwire.com/soft-tissue-sarcoma-market-is-estimated-to-witness-high-growth-owing-to-rising-rd-investments-in-immunotherapy/

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

What Are The Key Data Covered In This Soft Tissue Sarcoma Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Soft Tissue Sarcoma's growth between 2024 and 2031.

:- Accurate calculation of the size of the Soft Tissue Sarcoma and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Soft Tissue Sarcoma Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Soft Tissue Sarcoma vendors

FAQ’s

Q.1 What are the main factors influencing the Soft Tissue Sarcoma?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Soft Tissue Sarcoma companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Soft Tissue Sarcoma’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[industrynewsupdates]

Blood Screening Market Analysis, Opportunities And Forecast Report 2024-2030

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly. 

Blood Screening Market Segmentation

Grand View Research has segmented the global blood screening market based on technology, product, and region:

Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Nucleic Acid Amplification Test (NAT)

• ELISA

• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

• Next Generation Sequencing

• Western Blotting

Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagent

• Instrument

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global embolic protection devices market size was valued at USD 612.9 million in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030. 

• The global covered stent market size was estimated at USD 1.13 billion in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030. 

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.

For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.

Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.

Key Blood Screening Companies:

• Abbott

• Danaher Corporation (Beckman Coulter)

• Becton Dickinson and Company

• Bio-Rad Laboratories, Inc.

• Hoffman-La Roche Ltd.

• Grifols, S.A.

• Ortho-Clinical Diagnostics, Inc.

• Siemens Healthcare GmbH

• Thermo Fisher Scientific, Inc.

• SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research. 

[credenceresearchdotblog]

The global breast cancer liquid biopsy market has witnessed steady growth in recent years and is expected to grow at a CAGR of 22.7% between 2023 and 2030. The market was valued at USD 0.3 billion in 2022 and is expected to reach USD 1.25 billion in 2030. Breast cancer remains one of the most common and deadliest cancers among women worldwide, driving a significant demand for innovative diagnostic and monitoring tools. In recent years, the liquid biopsy market for breast cancer has gained momentum, promising to revolutionize the way clinicians approach cancer detection and management. This article delves into the current state of the breast cancer liquid biopsy market, its potential impact on patient outcomes, and the future of this burgeoning field.

Browse the full report at https://www.credenceresearch.com/report/breast-cancer-liquid-biopsy-market

Understanding Liquid Biopsy

Liquid biopsy is a non-invasive diagnostic method that analyzes circulating tumor DNA (ctDNA), RNA, or other biomarkers present in a patient's blood or other bodily fluids. Unlike traditional tissue biopsies, which require surgical procedures to obtain tissue samples, liquid biopsies can be performed through a simple blood draw. This method offers several advantages, including reduced patient discomfort, lower risk of complications, and the ability to monitor cancer dynamics over time.

Market Overview

The breast cancer liquid biopsy market is experiencing rapid growth, driven by advances in genomic technologies, increasing prevalence of breast cancer, and a shift towards personalized medicine. According to recent market research, the global liquid biopsy market was valued at approximately $4 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of around 20% over the next five years.

Several factors contribute to this robust growth:

1. Technological Advancements: Innovations in next-generation sequencing (NGS) and molecular profiling have significantly enhanced the accuracy and sensitivity of liquid biopsies. These technologies enable the detection of minute quantities of ctDNA, which is crucial for early cancer detection and monitoring.

2. Increased Breast Cancer Incidence: With the rising incidence of breast cancer globally, there is an increased demand for effective diagnostic and monitoring tools. Liquid biopsy offers a promising solution for early detection, minimal residual disease (MRD) monitoring, and assessing treatment efficacy.

3. Personalized Medicine: The trend towards personalized medicine is driving the adoption of liquid biopsies. By providing real-time insights into the genetic makeup of tumors, liquid biopsies enable clinicians to tailor treatments to individual patients, improving outcomes and reducing unnecessary side effects.

Clinical Applications

The clinical applications of breast cancer liquid biopsies are diverse and impactful:

1. Early Detection: Liquid biopsies have the potential to detect breast cancer at its earliest stages, even before symptoms appear or traditional imaging techniques can identify tumors. This early detection can lead to timely interventions and improved survival rates.

2. Monitoring Disease Progression: Liquid biopsies are valuable tools for tracking disease progression and assessing treatment response. They can detect changes in ctDNA levels, providing insights into how well a patient is responding to therapy and whether the cancer is becoming resistant to treatment.

3. Minimal Residual Disease Detection: After initial treatment, liquid biopsies can be used to detect residual disease that may not be visible through imaging. This helps in identifying patients at risk of relapse and guiding subsequent treatment strategies.

Challenges and Opportunities

Despite its potential, the liquid biopsy market faces several challenges:

1. Standardization and Validation: There is a need for standardized protocols and validation of liquid biopsy assays to ensure consistent and reliable results across different laboratories and clinical settings.

2. Regulatory Hurdles: Navigating regulatory pathways for liquid biopsy tests can be complex, with varying requirements across different regions. Regulatory approvals are crucial for widespread adoption and clinical integration.

3. Cost and Accessibility: While liquid biopsies offer numerous benefits, the cost of advanced genomic technologies can be high, potentially limiting access for some patients and healthcare systems. Efforts to reduce costs and improve accessibility are essential for broader adoption.

Future Outlook

The future of the breast cancer liquid biopsy market looks promising, with ongoing research and development aimed at overcoming current challenges and expanding clinical applications. Innovations in technology, coupled with increasing awareness and investment in liquid biopsy research, are expected to drive continued growth in this field.

Key Players

The Menarini Group

NeoGenomics Laboratories

F. Hoffmann-La Roche Ltd

Myriad Genetics Inc

QIAGEN

Biocept Inc

Sysmex Corporation

Fluxion Biosciences Inc

Epic Sciences Inc

Thermo Fisher Scientific Inc

Segmentation

By Circulating Biomarker

Circulating Tumor Cells (CTCs)

Cell-free DNA (cfDNA)

Extracellular Vesicles (EVs)

Others

By End User

Reference Laboratories

Hospitals & Physician Laboratories

Others

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

France

The U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/breast-cancer-liquid-biopsy-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[msinsights]

Blood Collection Tubes For Liquid Biopsy Market Size, Share, Regional Demand, Top Vendors, Segmentation and Forecast by 2031

The Blood Collection Tubes for Liquid Biopsy Market, as analyzed by Metastat Insight, represents a vital segment within the broader landscape of medical diagnostics. These specialized tubes serve as critical components in liquid biopsy, a revolutionary technique that allows for the non-invasive detection and analysis of biomarkers circulating in bodily fluids, such as blood. This market plays a pivotal role in advancing the field of personalized medicine, offering clinicians and researchers a powerful tool for early cancer detection, monitoring treatment response, and guiding therapeutic decision-making. 

Get a Free Sample Report @ https://www.metastatinsight.com/request-sample/2721

Top Companies

Roche, Streck, Preanalytix, Norgen Biotek, Biocept, Menarini Silicon Biosystems, Exact Sciences Corporation, Invitek Diagnostics, Abbott Laboratories.

Moreover, the rise of precision medicine has fueled the adoption of liquid biopsy techniques in clinical practice. By analyzing circulating tumor DNA (ctDNA) and other biomarkers, clinicians can tailor treatment strategies to individual patients, optimizing therapeutic outcomes and minimizing adverse effects. This paradigm shift towards personalized medicine has propelled the demand for high-quality blood collection tubes that ensure reliable and reproducible sample collection for downstream molecular analysis 

Additionally, technological advancements in the field of liquid biopsy have expanded the scope and capabilities of blood collection tubes. Manufacturers are continuously innovating to develop tubes that offer improved sample stability, compatibility with automated processing systems, and enhanced sensitivity for detecting low-abundance biomarkers. These advancements have not only enhanced the performance of liquid biopsy assays but have also facilitated the integration of these techniques into routine clinical practice. 

Browse Complete Report @ https://www.metastatinsight.com/report/blood-collection-tubes-for-liquid-biopsy-market

Furthermore, the increasing adoption of liquid biopsy for cancer screening and monitoring has created lucrative opportunities for stakeholders in the blood collection tubes market. Diagnostic laboratories, biotechnology companies, and healthcare providers are investing in the development and commercialization of novel blood collection tubes optimized for liquid biopsy applications, aiming to capitalize on the growing demand for non-invasive cancer diagnostics. 

[tritonmarketresearchamey]

Tech Impact on Cardiovascular Ultrasound Market: Trends & Prospects

Cardiovascular diseases (CVDs) have now surpassed cancer as the leading cause of death worldwide, with nearly 17.9 million lives lost every year. They are a group of illnesses, such as coronary heart disease, rheumatic heart disease, cerebrovascular disease, and others, affecting the heart and blood vessels.

Early detection is crucial to prevent these fatalities and seek timely care. Also called cardiac ultrasound or echocardiography, cardiovascular ultrasound is an imaging system that performs a detailed clinical diagnosis of the heart and detects any underlying issues in a relatively shorter duration.

According to Triton Market Research, the global cardiovascular ultrasound market is likely to develop with a CAGR of 6.12% in the forecast period from 2022 to 2028. The rising prevalence of CVDs has enhanced the demand for echocardiography devices, which is expected to drive the global market.

Increased Disease Prevalence Worldwide – Causative Factors

In recent years, the prevalence of hypertension, high blood glucose levels, elevated blood lipid levels, obesity, etc., has increased, which are risk factors for CVDs. Obesity rates have ascended in France, affecting 17% of the population.

Also, the substantial rise in the geriatric population, which is prone to several health conditions due to aging, contributes largely to the increased disease burden. In Brazil, people aged 50-79 are the most affected. With $61.78 million, the country accounted for the largest share in Latin America’s cardiovascular ultrasound market in 2021.

Realizing the importance of timely disease diagnosis, the Government of Australia launched the Cardiovascular Health Mission in 2019, which brings together experts in this field to make transformative improvements for patients’ cardiac health. The Australian market is expected to grow the fastest in the Asia-Pacific, with a 7.89% CAGR.

Technological Advancements widen Market Scope

The cardiovascular imaging domain has evolved due to the developments in 2D, 3D/4D, and Doppler technologies in ultrasound imaging. Another technology is point-of-care ultrasound, which uses a portable system that enables assessing patients without requiring them to be physically present in a cardiology department.

Advancements in technology offer numerous benefits, such as real-time imaging, ionizing-radiation-free imaging, enhanced diagnostic accuracy, improved patient safety, etc., which have revolutionized the field of echocardiography.

At 6.87% of CAGR, Doppler imaging to show the fastest growth in the Technology segment

Doppler imaging technology can detect heart valve defects, congenital heart disease, blocked or bulging arteries, and other conditions. Doppler ultrasound systems are gaining popularity as they easily identify any problems associated with the blood flow within the heart, which are otherwise difficult to diagnose.

Lanmage’s C6 portable color Doppler ultrasound system, which offers excellent imaging quality, is equipped with powerful functions for use in cardiac, vascular, and other applications.

At 6.37% of CAGR, Fetal Echocardiography to witness rapid growth in the Type segment

Fetal echocardiography is a type of ultrasound test performed on pregnant women to examine the fetus’ heart for any structural or functional abnormalities. Its demand is rising due to increased detection rate of congenital anomalies, with congenital heart disease the most common anomaly.

LISENDO 880LE is a premium 3D/4D diagnostic ultrasound system by FUJIFILM Holdings Corporation is a preferred choice by several cardiologists for pediatric and fetal heart patients.

Companies leverage Technology with Innovative Developments

A majority of the key market players are headquartered in Europe (GE Healthcare, Siemens Healthineers, Esaote S.p.A.) and the Asia-Pacific (Dawei Medical, Leltek Inc, Zoncare), signifying the large consumer base in these regions. The industry rivalry is significantly high due to manufacturers launching new products incorporated with innovative features.

In August 2020, Netherlands-based Philips Healthcare launched the Affiniti CVx echocardiography solution. Equipped with breakthrough interventional features, it aims to support cardiology departments in delivering improved patient care.

In June 2021, Japan-based Canon Medical Corp launched the Aplio i-series/Prism Edition, with faster processing and highly detailed imaging capabilities, along with several other enhanced applications.

Artificial Intelligence to Shape Future Opportunities

The integration of artificial intelligence (AI) technology into numerous cardiac ultrasound systems has emerged as the latest trend. AI in echocardiography is vital for disease diagnosis, standard section recognition, left ventricle functionality assessment, and automatic cardiac cavity segmentation.

Besides, introducing AI in cardiovascular ultrasound imaging has eased the whole process by eliminating the need for unnecessary testing and minimizing the costs incurred.

In the coming years, artificial intelligence’s role in echocardiography would become far more pertinent in developing smart algorithms for identifying risk factors and providing a more precise diagnosis. AI incorporation thus lays the foundation for the future of the cardiovascular ultrasound market.

FAQs:

Q 1) What are the revenue estimates for the global market?

The global cardiovascular ultrasound market which was valued $1450.86 million in 2021 and is likely to reach $2194.06 million by 2028.

Q 2) Which are the key end-users of cardiovascular ultrasound systems?

Ambulatory Care Centers, Hospitals, Diagnostic Centers, and Other End-users.

[heathcareforallworld]

Analyzing the Growth of the Pancreatic Cancer Diagnosis Market to 2032

Pancreatic cancer remains one of the most lethal forms of cancer, with a high mortality rate due to its typically late diagnosis and aggressive nature. Advances in diagnostic technologies, however, are providing hope for earlier detection and improved outcomes. This article explores the pancreatic cancer diagnosis market, covering market size, share, industry trends, and forecast up to 2032. We will delve into market segmentation and regional analysis to provide a comprehensive overview of the market dynamics.

Market Overview

The global pancreatic cancer diagnosis market has been growing steadily, driven by the increasing incidence of pancreatic cancer and advancements in diagnostic technologies. Pancreatic cancer diagnosis Market Size was estimated at 3.64 (USD Billion) in 2023. The Pancreatic Cancer Diagnosis Market Industry is expected to grow from 3.81(USD Billion) in 2024 to 5.6 (USD Billion) by 2032. The pancreatic cancer diagnosis Market CAGR (growth rate) is expected to be around 4.92% during the forecast period (2024 - 2032).

Market Segmentation

Understanding the segmentation of the pancreatic cancer diagnosis market is crucial for identifying growth opportunities and tailoring strategies to meet specific needs. The market can be segmented based on diagnostic method, end-user, and region.

By Diagnostic Method:

Imaging Tests: Includes CT scans, MRI, and endoscopic ultrasound, which are commonly used for detecting and staging pancreatic cancer.

Biopsy: Tissue sampling techniques such as fine-needle aspiration and core needle biopsy are critical for confirming diagnosis.

Blood Tests: Biomarkers like CA 19-9 and genetic tests are becoming increasingly important for early detection and monitoring.

Molecular Diagnostics: Advanced techniques such as next-generation sequencing (NGS) and liquid biopsy are gaining traction for their accuracy and non-invasive nature.

By End-User:

Hospitals: The primary setting for comprehensive diagnostic procedures and treatment planning.

Diagnostic Laboratories: Specialized facilities offering advanced molecular and genetic testing.

Research Institutes: Contributing to the development of new diagnostic tools and methods through clinical trials and studies.

By Region:

North America: Leading the market with significant investments in healthcare infrastructure and research.

Europe: Strong market presence driven by robust healthcare systems and increasing cancer awareness.

Asia-Pacific: Expected to witness the highest growth rate due to improving healthcare access and rising cancer prevalence.

Latin America: Moderate growth with increasing awareness and improving diagnostic capabilities.

Middle East and Africa: Emerging market with potential growth driven by investments in healthcare and diagnostic technologies.

Regional Analysis

The pancreatic cancer diagnosis market exhibits significant regional variations, influenced by healthcare infrastructure, prevalence of the disease, and economic conditions.

North America:

The largest market for pancreatic cancer diagnosis, driven by high incidence rates and advanced healthcare facilities.

The U.S. dominates the region with substantial funding for cancer research and high adoption of advanced diagnostic technologies.

Europe:

Holds a significant market share with countries like Germany, France, and the U.K. leading in terms of diagnosis and treatment capabilities.

Government initiatives and public health programs aimed at early cancer detection contribute to market growth.

Asia-Pacific:

Expected to experience the fastest growth during the forecast period.

Rapid urbanization, increasing healthcare expenditure, and rising awareness about cancer screening are key drivers.

Latin America:

Moderate growth supported by improving healthcare infrastructure and increasing awareness about pancreatic cancer.

Brazil and Mexico are the major contributors to the market in this region.

Middle East and Africa:

The market is in the nascent stage but shows potential for growth due to increasing healthcare investments and rising incidence of cancer.

Efforts to improve diagnostic capabilities and cancer care services are underway.

Industry Trends

Several trends are shaping the pancreatic cancer diagnosis market, reflecting advancements in technology, healthcare practices, and patient preferences.

Rise of Molecular Diagnostics:

Molecular diagnostics, including NGS and liquid biopsy, are becoming more prominent due to their precision and non-invasive nature.

These technologies enable earlier detection and personalized treatment approaches.

Integration of Artificial Intelligence (AI):

AI and machine learning are being integrated into diagnostic imaging and data analysis to improve accuracy and speed.

AI algorithms assist in detecting subtle changes in imaging studies that may indicate early stages of pancreatic cancer.

Emphasis on Biomarkers:

Research into biomarkers like CA 19-9 and new genetic markers is expanding, providing tools for early detection and monitoring disease progression.

Biomarker-based tests are becoming more refined and widely available.

Advancements in Imaging Technologies:

Enhanced imaging techniques, such as high-resolution CT and MRI, provide better visualization of pancreatic tumors.

Endoscopic ultrasound (EUS) is becoming a standard tool for detailed imaging and biopsy.

Focus on Early Detection:

Public health initiatives and screening programs are increasingly focusing on early detection to improve survival rates.

Education and awareness campaigns aim to encourage individuals at high risk to undergo regular screening.

Telemedicine and Remote Diagnostics:

The adoption of telemedicine platforms is facilitating remote consultations and diagnostics, improving access to care.

Remote diagnostic tools and mobile health applications support patient monitoring and follow-up.

Market Forecast

The pancreatic cancer diagnosis market is expected to grow significantly over the next decade. Key factors driving this growth include:

Increasing Incidence of Pancreatic Cancer:

The rising global burden of pancreatic cancer, partly due to aging populations and lifestyle factors, fuels the demand for diagnostic solutions.

Improved understanding of genetic predispositions and risk factors contributes to the identification of high-risk individuals.

Technological Advancements:

Continuous innovation in diagnostic technologies, including molecular diagnostics, AI integration, and advanced imaging, enhances the market.

Research and development activities are likely to yield new, more effective diagnostic tools.

Rising Healthcare Expenditure:

Increased spending on healthcare, particularly in emerging economies, supports market growth.

Investments in healthcare infrastructure and cancer research are critical drivers.

Growing Awareness and Screening Programs:

Public health campaigns and screening programs promote early detection, which is crucial for improving outcomes.

Efforts to educate the public and healthcare providers about the importance of early diagnosis are gaining momentum.

Conclusion

The pancreatic cancer diagnosis market is assured of substantial growth, driven by increasing incidence rates, technological advancements, and evolving healthcare practices. With diverse diagnostic methods and significant regional variations, the market offers numerous opportunities for stakeholders. As the global focus on early cancer detection intensifies, the demand for effective and innovative diagnostic solutions will continue to rise, making the pancreatic cancer diagnosis market a critical component of cancer care strategies worldwide.

[healthcaremarketanalysis]

Blood Screening Market worth $3.4 billion by 2028

Blood Screening Market in terms of revenue was estimated to be worth $2.4 billion in 2023 and is poised to reach $3.4 billion by 2028, growing at a CAGR of 7.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growth in this market is mainly driven by the growing requirement for donated blood, the rising number of blood donations around the world, and the ever-increasing infectious diseases. However, operational barriers and the high cost of Blood screening instruments is likely to hamper the growth of blood screening market.

Download an Illustrative overview:

Browse in-depth TOC on "Blood Screening Market"

189 - Tables

45 - Figures

220 – Pages

The Reagents & Kits segment is expected to account for the largest share in 2022.

Based on product, the blood screening market is segmented into reagents & kits, instruments, and software & services. Increase in demand and continuous use of the reagents and kits during blood transfusion processes, post blood donations is responsible for the large segment of this segment.

Nucleic Acid Test segment aimed the highest share during the forecast period

The blood screening market is segmented into nucleic acid tests (NAT), serology/immunoassay, rapid tests, western blot assays, and next-generation sequencing (NGS). In 2022, the nucleic acid test (NAT) segment accounted for the largest share of the blood screening market. From all the other technologies, NAT provides high precision, sensitivity and accuracy for blood screening and therefore, holds the largest share.

North America has the upper hand in the global Blood screening market

By regional segmentation, the blood screening market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Africa. North America has the largest share and is continuing to dominate the blood screening market. The factors responsible for the large share of North America in this market are the increasing prevalence of infectious diseases, rising awareness in blood donations, and the growing healthcare system that is highly developed in the US and Canada.

Request Sample Pages:

Blood Screening Market Dynamics:

Drivers:

Increasing number of blood donations worldwide

Restraints:

Alternative technologies

Opportunities:

Emerging markets

Challenge:

High cost of blood screening technologies

Key Market Players:

The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott Laboratories, Inc. (US), Bio-Rad Laboratories, Inc. (US), Danaher (Beckman Coulter, Inc.) (US), bioMérieux (France),  Hologic (US), Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), DiaSorin (Italy), Siemens Healthineers (Germany), QuidelOrtho Corporation (US), Merck KGaA (Germany), Revvity (Earlier known as PerkinElmer Inc.) (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), J. Mitra & Co. Pvt. Ltd. (India) and Tulip Diagnostics (India).

Recent Developments:

In February 2023, Thermo Fisher Scientific Inc. (US) acquired TIB Molbiol (Germany), to expand its PCR test portfolio with a wide range of assays for infectious diseases.

In December 2021, Hologic, Inc. (US) launched Panther Trax for high-volume molecular testing.

In May 2021, Beckmann Coulter (US) launched SARS-CoV-2 IgG.

In September 2021, Roche Diagnostics (Switzerland) acquired TIB Molbiol Group (Germany). This acquisition will enhance Roche's broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.

Inquiry Before Buying:

Blood Screening Market Advantages:

Early Disease Detection: Blood screening allows for the early detection of various diseases, including infections, cancers, and chronic conditions. Early diagnosis often leads to more effective treatment and improved patient outcomes.

Preventative Medicine: It enables preventative measures by identifying risk factors and potential health issues before they become serious. This proactive approach can lead to better health management and reduced healthcare costs.

Transfusion Safety: Blood screening is vital in ensuring the safety of blood transfusions. It screens for infectious agents like HIV, hepatitis, and syphilis, minimizing the risk of transmitting diseases through donated blood.

Population Health Management: Blood screening data can be analyzed on a population level, helping healthcare systems identify trends, allocate resources more effectively, and develop targeted public health interventions.

Personalized Medicine: Advances in blood screening techniques, such as genetic testing, allow for personalized treatment plans tailored to an individual's genetic makeup, improving the effectiveness of therapies and reducing adverse reactions.

Research and Drug Development: Blood screening plays a pivotal role in clinical trials and drug development, providing insights into treatment efficacy, patient response, and biomarker identification.

Point-of-Care Testing: Point-of-care blood screening devices enable rapid diagnostics in diverse settings, from clinics to remote areas, facilitating timely medical interventions and reducing the burden on healthcare facilities.

Healthcare Efficiency: Automating blood screening processes increases efficiency, reduces human error, and speeds up results, allowing healthcare providers to make quicker and more informed decisions.

Global Health: Blood screening contributes to global health efforts by identifying and controlling infectious diseases, making it an essential tool in disease surveillance and outbreak management.

Improved Quality of Life: Ultimately, the blood screening market's advantages contribute to an overall improvement in the quality of life for individuals and communities, promoting better health and well-being.

In summary, the blood screening market's advantages encompass early detection, preventative care, safety, personalized medicine, research, and healthcare efficiency, all of which have a profound impact on healthcare outcomes and public health.

Related Reports:

[wellnessweb]

Regional Breakdown of the PET Market Size

The Positron Emission Tomography (PET) Market size was estimated at USD 2.6 billion in 2023 and is expected to reach USD 4.30 billion by 2031 with a growing CAGR of 5.9% during the forecast period of 2024-2031.The Positron Emission Tomography (PET) market is a dynamic landscape at the intersection of cutting-edge medical technology and diagnostics. As demand grows for precise, non-invasive imaging techniques in healthcare, PET stands out for its ability to provide detailed insights into metabolic processes at the molecular level.

Advancements in radiopharmaceuticals and imaging hardware continue to drive innovation, enhancing PET's diagnostic accuracy and expanding its applications across oncology, neurology, and cardiology. With increasing investments in research and development, coupled with rising healthcare expenditure globally, the PET market is poised for significant growth, promising improved patient outcomes through early detection and personalized treatment strategies.

Get Sample Of This Report @ https://www.snsinsider.com/sample-request/3443

Segmentation View

By Product

PET/CT Systems

Low Slice Scanners

Medium Slice Scanners

High Slice Scanners

PET/MRI Systems

By Application

Oncology Applications

Neurological Applications

Cardiovascular Applications

Other Applications

By End User

Hospital & Surgical Centers

Diagnostic & Imaging Clinics

Ambulatory Care Centers

Other End Users

Russia-Ukraine War Impact on Positron Emission Tomography  Market

The analysis also contains significant data on the actual impacts of the conflict between Russia and Ukraine on the world market. The essay goes into great detail about a variety of global regions and how the war has affected their economies.

Competitive Scenario

This research gave readers a realistic image of the sector by outlining the full competitive landscape and the key providers' commodities supply, which was scattered across a wide range of geographical areas. For the forecast period, the paper provides the most recent market forecast analyses. To help enterprises comprehend the competitive climate of the top global suppliers of Positron Emission Tomography  Market , the study provides an in-depth analysis of industry competition as well as a synopsis of Porter's Five Forces model.

Report Conclusion

The Positron Emission Tomography  Market research study covers four levels of depth, including supply chain analysis, top-level firm market share analysis, business analysis (industry trends), and brief sector profiles, to name a few. The key ideas of the business environment, high-growth markets, high-growth countries, significant industry differences, business variables, and restrictions are also covered in this study.

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

Glaucoma Therapeutics Market Analysis

AI in Cancer Diagnosis Market Analysis

Blood Group Typing Market Analysis

DNA Synthesis Market Analysis

Genomics Services Market Analysis

[businessindustry]

At-Home Testing Market Global Opportunities by Regions and Growth Status by 2032

The Reports and Insights, a leading market research company, has recently releases report titled “At-Home Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global At-Home Testing Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the At-Home Testing Market?

The global at-home testing market was valued at US$ 7.2 Billion in 2023 and is expected to register a CAGR of 4.2% over the forecast period and reach US$ 10.4 Bn in 2032.

What are At-Home Testing?                                                                                                                                                                            

At-home testing refers to medical or diagnostic tests that individuals can conduct independently, without the supervision of healthcare professionals or the need for a laboratory. These tests are designed to be convenient and accessible, offering quick results for monitoring various health conditions or parameters from the comfort of one's home. At-home testing kits cater to diverse needs such as screening for infectious diseases, managing chronic conditions like diabetes, assessing fertility, and detecting genetic predispositions. Technological advancements have improved the accuracy and reliability of these tests, making them increasingly favored for proactive health monitoring and early detection.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2349

What are the growth prospects and trends in the At-Home Testing industry?

The at-home testing market growth is driven by various factors and trends. The at-home testing market is growing rapidly, fueled by a rising consumer preference for convenient and accessible diagnostic solutions. These tests enable individuals to monitor their health independently, offering a broad range of applications including screening for infectious diseases, managing chronic conditions, evaluating fertility, and genetic testing. Advancements in technology have enhanced the accuracy, reliability, and user-friendliness of at-home testing kits, driving their popularity for proactive health monitoring and early detection. North America, Europe, and Asia-Pacific are key regions driving market growth, characterized by competitive dynamics among established companies and ongoing innovations in test development and distribution. Hence, all these factors contribute to at-home testing market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Product

Digital Monitoring Instruments

Cassettes

Midstream

Strips

Cups

Dip Cards

Test Panels

Sample collection kits

Others

By Application

Blood Glucose Testing

Pregnancy & Fertility Testing

Cancer Testing

STD/ STI Testing

Testosterone

Drug Abuse Testing

Cholesterol Testing

Thyroid Testing

Others

North America

United States

Canada

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Poland

Benelux

Nordic

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

ASEAN

Australia & New Zealand

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

Saudi Arabia

South Africa

United Arab Emirates

Israel

Rest of MEA

Who are the key players operating in the industry?

The report covers the major market players including:

Becton, Dickinson and Company

Abbott

ACCESS BIO

CELLTRION INC

Siemens Healthcare GmbH

ACON Laboratories Inc

ARKRAY, Inc, F

Hoffmann-La Roche Ltd

OraSure Technologies Inc

Quest Diagnostics

Bionime Corporation

Btnx Inc

iHealth Labs Inc

InBios International, Inc. USA

Everlywell

LetsgetChecked

View Full Report: https://www.reportsandinsights.com/report/At-Home Testing-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: sales@reportsandinsights.com Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

[researchrealmblog]

Application of Terahertz Technology in Early, Non-Invasive Detection of Cancer

Terahertz (THz) is a unit of measurement of frequency equivalent to 1 trillion hertz (1,012 Hz). It generally denotes the frequency of electromagnetic waves, which are part of the electromagnetic spectrum not visible to the naked eye and lie between the infrared and microwave ranges.

The terahertz technology market is experiencing growth and is projected to reach USD 2,272.7 million by 2030.

Is Terahertz Technology a Brand-New Technology?

THz technology is not new. It has been examined since the 1960s, but in the past, it had diverse names like sub-millimeter, extreme infrared, and millimeter. The growth of terahertz technology depends heavily on developments in space science and radio astronomy.

What Are the Benefits of Terahertz-Range Frequencies?

Terahertz waves are non-invasive and non-ionizing. Because of its less energy characteristics, terahertz radiation is not damaging to humans and animals. And it can enter numerous materials. Even if an individual is wearing clothes, the clothes are translucent to terahertz, just like the king in “The Emperor’s New Clothes”.

Terahertz is a type of electromagnetic wave that occurs in the natural world. The human body produces this electromagnetic wave all the time and releases and spreads outward. Thus, the use of terahertz sensors can sense knives, guns, and other “opaque” objects that are not evident to the naked eye, which means that the precise location of the concealed objects can be known without a body search.

What Is the Use of Terahertz Technology?

Terahertz (THz) technology is extensively Utilized in lab research, military, homeland security, and military and industrial non-destructive testing (NDT). As per a report, in 2021, the laboratory research field was responsible for 53.11% of the industry demand for terahertz (THz) technology.

Terahertz (THz) technology applications are segmented into 3 categories: terahertz communication, terahertz spectroscopy, and terahertz imaging systems. Terahertz imaging holds a significant position in terahertz technology with an industry share of around 64.85% in 2021.

Applications of Terahertz Technology in Healthcare

Terahertz (THz) light (Tera =101, 1 THz =1×101 Hz) is a million times lesser frequency than X-rays and is non-ionizing. Thus, it would be harmless and looked-for to utilize THz light for medicinal imagery for both diagnostic and screening drives if the technology can be advanced properly.

THz light is powerfully captivated by intermolecular bonds e.g., hydrogen bonds existing in water and N-H bonds existing in proteins. This means it is quite delicate to subtle changes like augmented water content or blood flow which can be because of the existence of illness. THz light is also able to examine the molecular structure of chemicals and resolve thin layers of materials e.g., medicinal tablet coatings and the stratum corneum of the skin (in certain locations).

Non-Invasive Technique for Early Detection of Cancer

The latest research intended to detect terahertz properties on breast, skin cancer, and colon cancer tissues found that the refractive index and preoccupation coefficient of the tumor tissue are advanced in contrast to the normal tissue. This division is possible because of higher water content and physical changes that happen in carcinoma (e.g., augmented cell and protein density observed in cells affected by disease).

Source: P&S Intelligence